Intensity-modulated ventricular irradiation for intracranial germ-cell tumors: Survival analysis and impact of salvage re-irradiation

PLoS One. 2019 Dec 20;14(12):e0226350. doi: 10.1371/journal.pone.0226350. eCollection 2019.

Abstract

Background and purpose: The roles of surgery, chemotherapy, and parameters of radiation therapy for treating very rare central nervous system germ cell tumors (CNS-GCT) are still under discussion. We aimed to evaluate the survival and recurrence patterns of patients with CNS-GCT treated with chemotherapy followed by whole ventricle irradiation with intensity-modulated radiation therapy.

Materials and methods: We reviewed the clinical outcomes of 20 consecutive patients with CNS-GCT treated with chemotherapy and intensity-modulated radiation therapy from 2004 to 2014 in two partner institutions.

Results: Twenty children with a median age of 12 years were included (16 males). Sixteen tumors were pure germinomas, and 4 were non-germinomatous germ cell tumors (NGGCT). All patients were treated with intensity-modulated radiation therapy guided by daily images, and 70% with volumetric intensity-modulated arc radiotherapy additionally. The median dose for the whole-ventricle was 25.2 Gy (range: 18-30.6 Gy) and 36 Gy (range: 30-54 Gy) for the tumor bed boost. The median post-radiation therapy follow-up was 57.5 months. There were 3 recurrences (2 NGGCT and 1 germinoma that recurred as a NGGCT), with 1 death from the disease and the other 2 cases each successfully rescued with chemotherapy and craniospinal irradiation. The overall survival at 5 years was 95% and disease-free survival was 85%.

Conclusions: The results of this study suggest that the combined use of chemotherapy followed by whole ventricle irradiation with intensity-modulated radiation therapy is effective for CNS-GCTs, especially pure germinomas. Even being rescued with craniospinal irradiation, the NGGCT cases have markedly worse prognoses and should be more rigorously selected for localized treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Brain Neoplasms / radiotherapy*
  • Carboplatin / administration & dosage
  • Carboplatin / therapeutic use
  • Chemoradiotherapy
  • Child
  • Cranial Irradiation
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / therapeutic use
  • Dose Fractionation, Radiation
  • Etoposide / administration & dosage
  • Etoposide / therapeutic use
  • Female
  • Humans
  • Male
  • Neoplasms, Germ Cell and Embryonal / drug therapy*
  • Neoplasms, Germ Cell and Embryonal / mortality
  • Neoplasms, Germ Cell and Embryonal / radiotherapy*
  • Radiotherapy, Intensity-Modulated
  • Retrospective Studies
  • Salvage Therapy
  • Survival Analysis
  • Treatment Outcome

Substances

  • Etoposide
  • Cyclophosphamide
  • Carboplatin

Grants and funding

This study was partially supported by the Instituto Israelita de Responsabilidade Social (the foundation that supports research and other projects conducted in Hospital Israelita Albert Einstein, https://www.einstein.br/sobre-einstein). This entity took no part in the study design, data collection, or interpretation of results. There is no “grant protocol number” for this support.